Side-by-side · Research reference
PancragenvsTeriparatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BFDA-ApprovedHUMAN-REVIEWED10/62 cited
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
01Mechanism of Action
Parameter
Pancragen
Teriparatide
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Feedback intact?
Yes — preserves physiological glucose-insulin response
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Teriparatide
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Frequency
Once daily for 10 daysGoncharova 2014
Once daily
Intermittent administration preserves anabolic effect.
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
RCT / FDA-approved
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
Standard dose (osteoporosis)
—
20 mcg / day
FDA-approved regimen for severe osteoporosis.
Maximum duration
—
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
Hypoparathyroidism dose
—
20 mcg / day
Used off-label for chronic hypoparathyroidism.
Pelvic fragility fractures
—
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
Timing
—
Morning or evening (flexible)
Storage
—
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
Pharmacogenetics
—
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
03Metabolic / Fat Loss Evidence
Parameter
Pancragen
Teriparatide
Fat loss application
—
None — teriparatide is a bone anabolic agent without direct lipolytic activity
04Side Effects & Safety
Parameter
Pancragen
Teriparatide
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
—
Hypercalcemia
—
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
Orthostatic hypotension
—
Dizziness, lightheadedness within hours of injection
Nausea
—
Common, usually mild and transient
Leg cramps / Arthralgia
—
Musculoskeletal pain reported in clinical trials
Hypercalciuria
—
Increased urinary calcium excretion; monitor for nephrolithiasis risk
Osteosarcoma (black box warning)
—
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
Injection site reaction
—
Erythema, bruising, pain (uncommon)
Absolute Contraindications
Pancragen
—Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
05Administration Protocol
Parameter
Pancragen
Teriparatide
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
5. Monitoring
—
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
6. Calcium and vitamin D supplementation
—
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.